دورية أكاديمية
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
| العنوان: | Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience. |
|---|---|
| المؤلفون: | Yiğit Kaya S; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Turkey. Electronic address: sureyya.yigitkaya@medipol.com.tr., Mutlu YG; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Malkan ÜY; Department of Hematology, Faculty of Medicine, Hacettepe University, Turkey., Mehtap Ö; Department of Hematology, Faculty of Medicine, Kocaeli University, Turkey., Keklik Karadağ F; Department of Hematology, Faculty of Medicine, Ege University, Turkey., Korkmaz G; Department of Hematology, Ankara Bilkent City Hospital, Turkey., Elverdi T; Department of Hematology, Cerrahpaşa Faculty of Medicine, Istanbul University, Turkey., Saydam G; Department of Hematology, Faculty of Medicine, Ege University, Turkey., Özet G; Department of Hematology, Ankara Bilkent City Hospital, Turkey., Ar MC; Department of Hematology, Cerrahpaşa Faculty of Medicine, Istanbul University, Turkey., Melek E; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Maral S; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Kaynar L; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Sevindik ÖG; Department of Hematology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey. |
| المصدر: | Leukemia research [Leuk Res] 2024 May; Vol. 140, pp. 107495. Date of Electronic Publication: 2024 Mar 29. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford ; New York : Pergamon Press |
| مواضيع طبية MeSH: | Leukemia, Hairy Cell*/drug therapy , Leukemia, Hairy Cell*/pathology , Vemurafenib*/administration & dosage , Vemurafenib*/therapeutic use , Vemurafenib*/adverse effects , Rituximab*/administration & dosage , Rituximab*/therapeutic use , Rituximab*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Middle Aged ; Female ; Retrospective Studies ; Aged ; Adult ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Treatment Outcome ; Aged, 80 and over ; Drug Resistance, Neoplasm |
| مستخلص: | Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. The BRAF V600E mutation prevalent in HCL patients provides a target for treatment with vemurafenib. Patients and Methods: This multicenter retrospective study included nine patients with relapsed/refractory (R/R) HCL from six different centers. Patient data included demographics, prior treatments, clinical outcomes, and adverse events. Results: Patients received different treatment regimens between centers, including vemurafenib alone or in combination with rituximab. Despite the differences in protocols, all patients achieved at least a partial response, with seven patients achieving a complete response. Adverse events were generally mild with manageable side effects. The absence of myelotoxic effects and manageable side effects make BRAF inhibitors attractive, especially for patients ineligible for purine analogues or those with severe neutropenia. Conclusion: Single agent vemurafenib or in combination with rituximab appears to be a promising therapeutic option for R/R HCL. Further research is needed to establish standardized treatment protocols and to investigate long-term outcomes. Competing Interests: Declaration of Competing Interest All of the authors declare that there is no conflict of interest. (Copyright © 2024 Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: BRAF inhibitor; Hairy cell leukemia; Rituximab; Vemurafenib |
| المشرفين على المادة: | 207SMY3FQT (Vemurafenib) 4F4X42SYQ6 (Rituximab) EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) EC 2.7.11.1 (BRAF protein, human) |
| تواريخ الأحداث: | Date Created: 20240410 Date Completed: 20240504 Latest Revision: 20240615 |
| رمز التحديث: | 20240615 |
| DOI: | 10.1016/j.leukres.2024.107495 |
| PMID: | 38599153 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-5835 |
|---|---|
| DOI: | 10.1016/j.leukres.2024.107495 |